Navigation Links
Columbus Center for Women’s Health Research is participating in an International Study for a New “Use-as-Needed” Treatment for Women with Sexual Dysfunction
Date:2/23/2013

Columbus, OH (PRWEB) February 23, 2013

Female Sexual Dysfunction affect women worldwide. Columbus Center for Women’s Health Research or CCWHR is participating in one of the largest clinical studies to ever explore a “use-as-needed” treatment, Tefina™, for women experiencing orgasmic disorder. The study, which will involve 240 patients in the U.S., Canada and Australia, will evaluate if there is an increase in the occurrence of orgasm over the treatment period, compared against baseline levels.

Recently there has been a lot of media coverage surrounding this study with references to Tefina as “female-viagra”. Tefina™ is a nasal gel containing bio-identical testosterone and is gently placed on the inside wall of the nose with an easy to use applicator 1-4 hours before sexual activity. The gel is designed to adhere to the nasal wall and not drip out, allowing the testosterone to be absorbed through the nasal lining within 10-15 minutes of application. Female Orgasmic Disorder, also known as Female Anorgasmia, is defined as the persistent or recurrent delay in or absence of orgasm. Although this condition is estimated to affect up to 1 in 5 women worldwide, there are no FDA approved treatments.

“Tefina™ is a potentially revolutionary treatment to restore women’s ability to obtain orgasm and sexual satisfaction” says Dr. Kingsberg, Primary Investigator of the study and Chief of Behavioral Medicine at UH MacDonald Women’s Hospital. “Low sexual satisfaction is linked to a lower sense of well-being as well as to tension in relationships. We are hopeful that this be a real help for patients who say ‘sex has become a chore.’

Participants must be aged 18 to 65 and be unable to be sexually satisfied after previously having had no problems. David J. Portman, MD is the PI for the local trial site at Columbus Center for Women’s Health Research. Dr. Portman founded the Columbus Center for Women's Health Research in 1997 and has conducted many clinical studies in hormone therapy, osteoporosis, contraception, endocrine and heart disease and other issues pertaining to OB/GYN. In addition, he is recognized as one of the country's leading experts in menopause and the treatment options available to women today. He lectures extensively across the country on this and related topics, and frequently consults on issues related to Women's Health. For more information on current studies, call 614-861-6707 or visit http://www.ccwhr.com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10457472.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Hearing Health Solutions Now Makes Finding Hearing Aids in Columbus, OH Easier with Complimentary Hearing Screenings
2. Columbus Allergist Dr. Summit Shah Discusses Recent Findings on Food Allergies and Exercise-Induced Anaphylaxis
3. Milford, Ohio: Periodontists of the Ohio Valley Center for Periodontics & Implants Now Bring a Modern Gum Surgery Alternative to their Local Gum Disease Patients
4. Mesothelioma Victims Center's Now Urges All US Navy Veterans Diagnosed With Mesothelioma Cancer To Call Them For Contacts For The Best Mesothelioma Law Firms
5. The MS Center of Atlanta Partners with Georgia Partnership for TeleHealth
6. Save the Date Durand Community Blood Drives at the American Legion with the Rock River Valley Blood Center
7. Delray Recovery Center Treats Steroid and Performance Enhancing Drug Abuse
8. Lung Cancer Asbestos Victims Center Now Strongly Encourages Lung Cancer Victims To Call Them If They Were Exposed To Asbestos In Their Workplace-Possible Compensation
9. Mesothelioma Victims Center Now Urges All Victims Of Mesothelioma To Call Them For The Names Of Most Skilled Mesothelioma Law Firms-Because They Get The Best Results
10. The Center for Wound Healing, Inc. Acquires Assets from Restorix Health
11. Personal Enhancement Center Runs Sandy Holiday Fundraiser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 26, 2017 , ... Want to learn more about CRISPR-Cas ... that demonstrates how this advanced plant breeding technology is a more efficient way ... resources. It highlights the business’ principles, research and collaboration efforts in this area. ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: